GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Sino-American immunotherapy-focused biotech LTZ Therapeutics and UK pharma major GSK have entered into a strategic research ...

GSK teams with LTZ Therapeutics to co-develop next-gen myeloid-cell engager immunotherapies in oncology leveraging LTZ’s ...

The latest update is out from GlaxoSmithKline Pharmaceuticals Limited ( ($IN:GLAXO) ). GlaxoSmithKline Pharmaceuticals Limited has announced a ...

GSK Pharma share price fell 3 per cent after it reported a lower-than-expected top-line for the second quarter of the current financial year ...

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...

GSK’s entry into Oncology with the launch of specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) was well-received by healthcare professionals. Shares of GlaxoSmithKline ...

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. GSK has collected about 978 million pounds ($1.24 billion ...

Moderna has announced a $140 million investment to enhance its Massachusetts manufacturing capacity, a move that supports ...

GlaxoSmithKline Pharma has announced the appointment of Juby Chandy as Vice President, Finance Asia Pacific (APAC) region, ...

India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for ...